Sellas life sciences announces positive outcome of interim analysis for its pivotal phase 3 regal trial of gps in acute myeloid leukemia

- regal successfully passes event-driven (60 deaths) interim analysis for efficacy, futility, and safety: the independent data monitoring committee (idmc) recommended continuation of the clinical trial without modification –
GPS Ratings Summary
GPS Quant Ranking